|Bid||0.5556 x 800|
|Ask||0.5799 x 1000|
|Day's Range||0.5420 - 0.5859|
|52 Week Range||0.4500 - 6.1800|
|Beta (5Y Monthly)||-0.12|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 16, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
Subscribe to Yahoo Finance Plus to view Fair Value for AYTU
View more earnings on AYTUSee more from BenzingaFDA May Authorize Pfizer-BioNTech's COVID-19 Booster For 5-11 Year Kids Soon: NYTWarren Buffett Exits Wells Fargo And Buys Stake In Its Rival BankDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Quarterly Net Revenue Increased 79% Year-Over-Year to $24.2 Million, the Highest Revenue in Company HistoryStrategic Priorities Focused on Driving Revenue Growth, Increasing Financial Efficiencies and Performance and Preparing Pipeline for Long-term Value CreationENGLEWOOD, CO / ACCESSWIRE / May 16, 2022 / Aytu BioPharma, Inc.
Preclinical Proof-of-Concept Study Demonstrates Effectiveness of Healight in Delaying Time to Development of Ventilator-Associated PneumoniaENGLEWOOD, CO / ACCESSWIRE / April 25, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced positive results from a preclinical pilot study showing that administration of its Healight™ ultraviolet light A (UVA) endotracheal catheter delayed the time to development of